FDA to Convene Pharmacy Compounding Advisory Committee in July Mark your calendar. July 23 24. FDA advisory committee reviewing BPC 157, TB 500, MOTS C, semax, epitalon, KPV, and DSIP for the 503A compounding list. The peptide landscape could shift significantly. Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law Peptides are starting to move back into the conversation., After years of restriction under the FDAs 503A Category 2 list, were now seeing momentum toward re evaluation and potential reintroduction FDA May Reverse Ban on 14 PeptidesWhat It Means for Your Beauty Routine Allure fda warning bpc 157 peptide products New Details 157